OrthoPediatrics corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
39.3%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$265.1Mnext fiscal year
FY EPS (est.)
-$1.05next fiscal year
Monitoring Framework
Key Performance Indicators
Worldwide Net Revenue Quarterly59.4MTarget: 263000000 to 267000000
Adjusted EBITDA Quarterly2.2M
Gross Profit Margin Quarterly73.0%Target: Stable at ~73%
Watch Items
- Integration of acquired Brazilian distributor and transition from wholesale to direct salesTrigger: Margin and cash flow improvements by late 2026, revenue impact from 2027Action: Monitor international segment revenue growth and gross margin expansion
- Consigned implant inventory and set deployment levelsTrigger: Annual set deployment target of approximately $10 millionAction: Review quarterly capital expenditure and set deployment efficiency metrics
Research as of 19 Jun 2026